Merus NV’s (MRUS) Outperform Rating Reiterated at Wedbush

Merus NV (NASDAQ:MRUS)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a note issued to investors on Tuesday. They presently have a $32.00 target price on the biotechnology company’s stock. Wedbush’s target price would suggest a potential upside of 76.02% from the stock’s previous close.

Other analysts have also issued reports about the company. Citigroup Inc lowered Merus NV from a “buy” rating to a “neutral” rating and set a $31.00 target price on the stock. in a report on Tuesday, March 21st. ValuEngine raised Merus NV from a “sell” rating to a “hold” rating in a report on Saturday, May 20th. Jefferies Group LLC reaffirmed a “buy” rating and set a $33.00 target price on shares of Merus NV in a report on Wednesday, April 26th. Finally, Zacks Investment Research lowered Merus NV from a “hold” rating to a “sell” rating in a report on Friday, May 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $24.40.

Shares of Merus NV (NASDAQ:MRUS) traded down 7.65% during trading on Tuesday, reaching $16.79. The company’s stock had a trading volume of 36,414 shares. Merus NV has a one year low of $7.26 and a one year high of $33.63. The stock’s market cap is $270.07 million. The company has a 50-day moving average price of $20.29 and a 200-day moving average price of $21.94.

ILLEGAL ACTIVITY NOTICE: This article was reported by Mideast Time and is the sole property of of Mideast Time. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.mideasttime.com/merus-nvs-mrus-outperform-rating-reiterated-at-wedbush/1756862.html.

A number of hedge funds have recently bought and sold shares of MRUS. Geode Capital Management LLC acquired a new stake in shares of Merus NV during the first quarter valued at approximately $244,000. Spark Investment Management LLC acquired a new stake in shares of Merus NV during the first quarter valued at approximately $458,000. Renaissance Technologies LLC acquired a new stake in shares of Merus NV during the first quarter valued at approximately $549,000. Iguana Healthcare Management LLC raised its stake in shares of Merus NV by 16.7% in the first quarter. Iguana Healthcare Management LLC now owns 175,000 shares of the biotechnology company’s stock valued at $4,268,000 after buying an additional 25,000 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Merus NV during the fourth quarter valued at approximately $790,000. 29.03% of the stock is currently owned by hedge funds and other institutional investors.

Merus NV Company Profile

new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:MRUS”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Merus NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus NV and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.